Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

101.57 +0.03 (+0.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
From Exact Sciences Corp.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
From Exact Sciences Corp.
Via Business Wire
News headline image
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
EXAS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Exact Sciences Corporation is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Third Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Schedules Third Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
News headline image
New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
From Exact Sciences Corp.
Via Business Wire
News headline image
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Second Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Schedules Second Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Announces First-Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025
From Exact Sciences Corp.
Via Business Wire
News headline image
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.